Tarsons Products LimitedPharmaceuticals & HealthcareTARSONS
Q1 FY27 concall · earnings callTarsons Products Limited
Tarsons delivered strong 21% revenue growth in Q1 FY27, driven by domestic recovery and export rebound, but profitability was pressured by sharply higher raw material costs and new facility ramp-up expenses.
Numbers
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Consolidated Revenue | ₹110 Cr | 21% Y-o-Y | |
| Standalone Revenue | ₹86.1 Cr | 21% Y-o-Y | |
| Domestic Sales Growth | 17% | 17% Y-o-Y | |
| Export Growth | 29% | 29% Y-o-Y | |
| Standalone Gross Margin | 67.1% | — | |
| Consolidated EBITDA Margin | 23.6% | — | |
| Consolidated Cash Profit | ₹25.6 Cr | 18% Y-o-Y |
Financials
From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.
| Quarter | Revenue | Net profit (PAT) | Basic EPS |
|---|---|---|---|
| Q3 FY25 | ₹95.68 Cr+54.8% YoY-3.6% QoQ | ₹5.26 Cr-47% YoY-48.9% QoQ | ₹0.99-47.1% YoY-48.7% QoQ |
| Q2 FY25 | ₹99.25 Cr— YoY+17% QoQ | ₹10.29 Cr— YoY+156% QoQ | ₹1.93— YoY+157.3% QoQ |
| Q1 FY25 | ₹84.80 Cr— YoY-19.8% QoQ | ₹4.02 Cr— YoY-61% QoQ | ₹0.75— YoY-61.3% QoQ |
| Q4 FY24 | ₹105.72 Cr— YoY+71.1% QoQ | ₹10.32 Cr— YoY+3.9% QoQ | ₹1.94— YoY+3.7% QoQ |
| Q3 FY24 | ₹61.79 Cr— YoY— QoQ | ₹9.93 Cr— YoY— QoQ | ₹1.87— YoY— QoQ |
TL;DR
- Consolidated revenue grew 20.7% year-on-year to Rs 110.2 crores.
- Standalone revenue grew 21% to Rs 86.1 crores, the highest ever Q1.
- Domestic sales grew 17%, while exports rebounded strongly with 29% growth.
- Gross margin (standalone) fell to 67.1% due to raw material price spikes of 25-50%.
- EBITDA margin (consolidated) was 23.6%, impacted by higher costs and new facility expenses.
- Cash profit grew 18% year-on-year to Rs 25.6 crores.
Said on the call
“The performance reflects the resilience of our business model and our ability to deliver growth despite a challenging operating environment.”
From the Q&A
| Topic | What management said |
|---|---|
| Capacity Expansion & Delays | The Panchla facility commercial commissioning has been delayed to the second half of FY27 due to the sheer scale and external supplier challenges; Q1 revenue from it was from existing products, not new cell culture lines. |
| Debt & Depreciation | Gross debt is ~INR 380 crores, net debt ~INR 330-340 crores; FY27 depreciation is expected to peak at INR 105-110 crores, and net debt is targeted to reduce by ~INR 40 crores. |
| Raw Material Costs & Pricing | Raw material prices spiked 25-50%, leading to gross margin pressure; only marginal price increases were implemented domestically, with none in export markets, relying on rupee depreciation. |
| Growth Outlook & New Products | Management sees a 15%+ growth trajectory as sustainable, with the delta beyond that dependent on new products (like cell culture) and the export environment; new products are expected to contribute INR 65-70 crores in FY28. |
| Competition | Direct Chinese competition in India is limited to low-end segments not served by Tarsons, but intense Chinese competition persists in international markets; domestic market growth is returning to late single digits. |
| Export Market Challenges | The export environment remains challenging due to logistics, input costs, and U.S. tariff rumors, but inquiry levels are promising; management's current focus is on growing market share, not margins. |
Guidance
- Expect FY27 revenue growth of around 15%.
- Profit to remain relatively moderate in FY27 due to higher depreciation and interest costs from new CAPEX.
- Panchla and Amta facilities expected to contribute 20-25% of standalone revenues in FY28.
- New product portfolio (including cell culture) expected to contribute INR 65-70 crores in FY28.
- Annual maintenance CAPEX not expected to exceed INR 20-25 crores.
- Depreciation for FY27 expected to be INR 105-110 crores, the peak year.
- Net debt reduction target of ~INR 40 crores for FY27.
- Gross margins for FY27 could remain similar to Q1 levels, subject to volatile raw material prices.
Source
Summary written from the transcript filed by Tarsons Products Limited for the call held on 11 Aug 2026; published 18 Aug 2026, 21:23 IST.
More Q1 FY27 concalls ·How verification works ·Report an error